Evidence map›Paper›PMID 25332894›Full record

ReviewWorld journal of nephrology2014

Kidney regeneration: Where we are and future perspectives.

Joao Paulo Zambon, Renata S Magalhaes, Inkap Ko, Christina L Ross, Giuseppe Orlando, Andrea Peloso, Anthony Atala, James J Yoo

Open access · hybridAbstract readReview
In one paragraph

Review in World journal of nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joao Paulo ZambonJoao Paulo Zambon, Renata S Magalhaes, Inkap Ko, Christina L Ross, Giuseppe Orlando, Andrea Peloso, Anthony Atala, James J Yoo, Wake Forest Institute for Regenerative Medicine, North Carolina, NC 27104, United States.
Renata S MagalhaesJoao Paulo Zambon, Renata S Magalhaes, Inkap Ko, Christina L Ross, Giuseppe Orlando, Andrea Peloso, Anthony Atala, James J Yoo, Wake Forest Institute for Regenerative Medicine, North Carolina, NC 27104, United States.
Inkap KoJoao Paulo Zambon, Renata S Magalhaes, Inkap Ko, Christina L Ross, Giuseppe Orlando, Andrea Peloso, Anthony Atala, James J Yoo, Wake Forest Institute for Regenerative Medicine, North Carolina, NC 27104, United States.
Christina L RossJoao Paulo Zambon, Renata S Magalhaes, Inkap Ko, Christina L Ross, Giuseppe Orlando, Andrea Peloso, Anthony Atala, James J Yoo, Wake Forest Institute for Regenerative Medicine, North Carolina, NC 27104, United States.
Giuseppe OrlandoJoao Paulo Zambon, Renata S Magalhaes, Inkap Ko, Christina L Ross, Giuseppe Orlando, Andrea Peloso, Anthony Atala, James J Yoo, Wake Forest Institute for Regenerative Medicine, North Carolina, NC 27104, United States.
Andrea PelosoJoao Paulo Zambon, Renata S Magalhaes, Inkap Ko, Christina L Ross, Giuseppe Orlando, Andrea Peloso, Anthony Atala, James J Yoo, Wake Forest Institute for Regenerative Medicine, North Carolina, NC 27104, United States.
Anthony AtalaJoao Paulo Zambon, Renata S Magalhaes, Inkap Ko, Christina L Ross, Giuseppe Orlando, Andrea Peloso, Anthony Atala, James J Yoo, Wake Forest Institute for Regenerative Medicine, North Carolina, NC 27104, United States.
James J YooJoao Paulo Zambon, Renata S Magalhaes, Inkap Ko, Christina L Ross, Giuseppe Orlando, Andrea Peloso, Anthony Atala, James J Yoo, Wake Forest Institute for Regenerative Medicine, North Carolina, NC 27104, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2012, about 16487 people received kidney transplants in the United States, whereas 95022 candidates were on the waiting list by the end of the year. Despite advances in renal transplant immunology, approximately 40% of recipients will die or lose graft within 10 years. The limitations of current therapies for renal failure have led researchers to explore the development of modalities that could improve, restore, or replace the renal function. The aim of this paper is to describe a reasonable approach for kidney regeneration and review the current literature regarding cell sources and mechanisms to develop a bioengineering kidney. Due to kidneys peculiar anatomy, extracellular matrix based scaffolds are rational starting point for their regeneration. The perfusion of detergents through the kidney vasculature is an efficient method for delivering decellularizing agents to cells and for removing of cellular material from the tissue. Many efforts have focused on the search of a reliable cell source to provide enrichment for achieving stable renal cell systems. For an efficient bioengineered kidney, these cells must be attached to the organ and then maturated into the bioractors, which simulates the human body environment. A functional bioengineered kidney is still a big challenge for scientists. In the last ten years we have got many improvements on the field of solid organ regeneration; however, we are still far away from the main target. Currently, regenerative centers worldwide have been striving to find feasible strategies to develop bioengineered kidneys. Cell-scaffold technology gives hope to end-stage renal disease patients who struggle with morbidity and mortality due to extended periods on dialysis or immunosupression. The potential of bioengineered organ is to provide a reliable source of organs, which can be refunctionalized and transplanted.

Indexed as

DecellularizationExtra cellular matrixKidney regenerationRegenerative medicineStem cells

Identifiers

PMID25332894
PMCPMC4202490
OpenAlexW2081980812

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.